As we observed a reduction in the percentage of TIM-3 positivity after stimulation in T cell subsets and NK cells from glioblastoma patients, we determined whether the two ligands of TIM-3 (galectin-9 and HMGB1) that are significantly over-expressed in glioblastoma versus normal brain tissue and low-grade glioma (Supplementary Figure S4A–C) could modify the change in the percentage of TIM-3 positivity after stimulation in healthy donor CD4+ and CD8+ T cells and NK cells (Supplementary Figure S5A–C). This evidence concerns the gene LGALS9 and central nervous system cancer.